Cystic fibrosis (CF) manifests as a clinical syndrome\ncharacterized by chronic sinopulmonary infection as well as by\ngastrointestinal, nutritional, and other abnormalities.<\/p>\n\n\n\n
Lung damage secondary to chronic infection is the main\ndeterminant of morbidity and mortality in individuals with cystic fibrosis. CF\nindividuals are highly susceptible to bacterial infections in the respiratory\ntract and repeated and intensive antibiotic therapy is required to maintain\nlung function and quality of life and reduce exacerbations in infected\npatients.<\/p>\n\n\n\n
According to a study conducted by Jeffrey et al., 2002 it is\nestimated that 80\u201395% of patients with CF succumb to respiratory failure\nbrought on by chronic bacterial infection and concomitant airway inflammation.\nCystic fibrosis occurs in males and females with approximately equal\nfrequencies, though clinically male patients have slightly better health than\nfemale patients.<\/p>\n\n\n\n
Cystic fibrosis (CF) is an inherited disease, which causes\nproblems in the body’s cells that make salt, water, and mucus. There is no cure\nfor CF. It is a disease that gets worse over time. But better treatments can\nnow help people to live a longer and healthier life.<\/p>\n\n\n\n
CF individuals are highly susceptible to bacterial infections\nin the respiratory tract and repeated and intensive antibiotic therapy is\nrequired to maintain lung function and quality of life and reduce exacerbations\nin infected patients.<\/p>\n\n\n\n
Inhaled antibiotics have been used as a treatment for CF\nrespiratory tract infections since penicillin first became available.\nFosfomycin tobramycin (FTI) for inhalation has activity against anaerobic,\ngram-negative, and gram-positive bacteria, including methicillin-resistant\nStaphylococcus aureus (MRSA).<\/p>\n\n\n\n
The treatment of multidrug-resistant gram-negative bacteria\nin patients with CF with advanced lung disease is challenging given the\nintrinsic resistance of these organisms to antimicrobials of several different\nclasses.<\/p>\n\n\n\n
A number of different oral and intravenous antibiotics may\nbe combined to tailor antibiotic therapy as best as possible to particular\ncombinations of positive bacterial culture results.<\/p>\n\n\n\n
As molecular diagnostics for a wider range of bacteria in\nthe CF airway microbiome become available, better clinical trials are needed to\ninform the choice of antibiotics for long-term bacterial suppression and treatment.<\/p>\n\n\n\n
Key players, such as Insmed Incorporated, Aridis Pharma,\netc., are involved in developing therapies for the treatment of Chronic Lung\nInfections in Cystic Fibrosis. Arikayce (Insmed Incorporated), AR-501 (Aridis Pharma),\nand along with other compelling treatment options in the clinical trials is\nexpected to increase the overall market size of Chronic Lung Infections in\nCystic Fibrosis.<\/p>\n","protected":false},"excerpt":{"rendered":"
Cystic fibrosis (CF) manifests as a clinical syndrome characterized by chronic sinopulmonary infection as well as by gastrointestinal, nutritional, and other abnormalities. Lung damage secondary to chronic infection is the main determinant of morbidity and mortality in individuals with cystic fibrosis. CF individuals are highly susceptible to bacterial infections in the respiratory tract and repeated […]<\/p>\n","protected":false},"author":1,"featured_media":6087,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[195,6347,6346,16883,17788],"industry":[17225],"therapeutic_areas":[17243],"class_list":["post-6086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-cystic-fibrosis","tag-cystic-fibrosis-drug-market","tag-cystic-fibrosis-drugs","tag-cystic-fibrosis-market","tag-cystic-fibrosis-pipeline","industry-pharmaceutical","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"\n